Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Investigative Dermatology

• Publication date

  2016-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jid.2016.05.098PMID 27251789PMCID PMC6373467
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phosphoproteomic analysis of basal and therapy‐induced adaptive signaling networks in BRAF and NRAS mutant melanoma

  2015cited by this paper
• Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD.

  2015cited by this paper
• PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways

  2014cited by this paper
• Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers

  2014cited by this paper
• Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.

  2014cited by this paper
• Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.

  2014influential reference
• ER stress signaling in ARPE-19 cells after inhibition of protein kinase CK2 by CX-4945.

  2014cited by this paper
• Mutant NRASQ61 shares signaling similarities across various cancer types – potential implications for future therapies

  2014cited by this paper
• TPX2: of spindle assembly, DNA damage response, and cancer

  2014cited by this paper
• The protein interaction landscape of the human CMGC kinase group.

  2013cited by this paper
• The clinical significance of BRAF and NRAS mutations in a clinic‐based metastatic melanoma cohort

  2013cited by this paper
• Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

  2013cited by this paper
• Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes.

  2013cited by this paper
• NRAS mutant melanoma – undrugable?

  2013cited by this paper
• Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma

  2013cited by this paper
• Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

  2013cited by this paper
• NMR-based functional profiling of RASopathies and oncogenic RAS mutations

  2013cited by this paper
• NRAS mutant melanoma: biological behavior and future strategies for therapeutic management

  2013cited by this paper
• Activated Mutant NRasQ61K Drives Aberrant Melanocyte Signaling, Survival, and Invasiveness via a Rac1-Dependent Mechanism

  2012cited by this paper
• MMFPh: a maximal motif finder for phosphoproteomics datasets

  2012cited by this paper
• Phosphorylation of the Androgen Receptor by PIM1 in Hormone Refractory Prostate Cancer

  2012cited by this paper
• NRAS mutation status is an independent prognostic factor in metastatic melanoma

  2012influential reference
• Role of PRAS40 in Akt and mTOR signaling in health and disease.

  2012cited by this paper
• The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

  2012cited by this paper
• Hurdles and complexities of codon 13 KRAS mutations.

  2012cited by this paper
• Signalling to cancer cell invasion through PAK family kinases.

  2011cited by this paper
• Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

  2011influential reference
• Overexpression of 14-3-3ζ in cancer cells activates PI3K via binding the p85 regulatory subunit

  2011cited by this paper
• Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

  2010cited by this paper
• Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma

  2010influential reference
• Allosteric Modulation of Ras-GTP Is Linked to Signal Transduction through RAF Kinase*

  2010cited by this paper
• Protein Kinase CK2 in Health and Disease

  2009cited by this paper
• Faculty Opinions recommendation of Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.

  2008cited by this paper
• GEFs and GAPs: critical elements in the control of small G proteins.

  2007cited by this paper
• Differential oncogenic potential of activated RAS isoforms in melanocytes

  2007cited by this paper
• p38alpha: a suppressor of cell proliferation and tumorigenesis.

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• PRAS40 deregulates apoptosis in malignant melanoma.

  2007cited by this paper
• Ras oncogenes and their downstream targets.

  2007cited by this paper
• NetworKIN: a resource for exploring cellular phosphorylation networks

  2007cited by this paper
• Ras signaling from plasma membrane and endomembrane microdomains.

  2005cited by this paper
• Distinct sets of genetic alterations in melanoma.

  2005cited by this paper
• Regulation of protein kinases; controlling activity through activation segment conformation.

  2004influential reference
• Ras Activates the Epithelial Na+ Channel through Phosphoinositide 3-OH Kinase Signaling*

  2004cited by this paper
• Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics*

  2002cited by this paper
• The activation loop of phosphatidylinositol phosphate kinases determines signaling specificity.

  2000influential reference
• K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.

  2000cited by this paper
• Role of accurate mass measurement (+/- 10 ppm) in protein identification strategies employing MS or MS/MS and database searching.

  1999influential reference
• Cooperative effects of INK4a and ras in melanoma susceptibility in vivo.

  1997cited by this paper
• Characterization of a 78-residue fragment of c-Raf-1 that comprises a minimal binding domain for the interaction with Ras-GTP.

  1994cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984influential reference

• Modulation of the 14-3-3σ/C-RAF “Auto”inhibited Complex by Molecular Glues

  2026cites this paper
• Advances in Cutaneous Melanoma Therapy: The Emerging Role of CDK4/6 Inhibitors

  2025cites this paper
• DEAPR: Differential Expression and Pathway Ranking Tool Demonstrates NRASG12V and NRASG12D Mutations Have Differing Effects in THP-1 Cells

  2025cites this paper
• Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?

  2024cites this paper
• Reclassification of RAS/BRAF allele mutations predicts the survival benefit of triplet chemotherapy in metastatic colorectal cancer

  2024cites this paper
• Assessment of RAS-RAF-MAPK Pathway Mutation Status in Healthy Skin, Benign Nevi, and Cutaneous Melanomas: Pilot Study Using Droplet Digital PCR

  2024cites this paper
• Relative genotoxicity of polycyclic aromatic hydrocarbons inferred from free energy perturbation approaches

  2024cites this paper
• TGF-β1 activates neutrophil signaling and gene expression but not migration

  2023cites this paper
• TGF-β1 activates neutrophil signaling and gene expression but not migration

  2023cites this paper
• NRAS promotes the proliferation of melanocytes to increase melanin deposition in Rex rabbits.

  2022cites this paper
• PFKFB4 interacts with ICMT and activates RAS/AKT signaling-dependent cell migration in melanoma

  2022cites this paper
• Title: Designed sensors reveal normal and oncogenic Ras signaling in endomembranes and condensates

  2022cites this paper
• CK2 Regulation: Perspectives in 2021

  2021cites this paper
• Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

  2021cites this paper
• Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment

  2021cites this paper
• Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants.

  2020cites this paper
• STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations

  2020influential citation
• The effects of mutant Ras proteins on the cell signalome

  2020cites this paper
• Phosphoproteomic strategies in cancer research: a minireview.

  2020cites this paper
• Mutacije gena BRAF i NRAS u pacijenata s melanomom kože čiji su tkivni uzorci analizirani tijekom 2017. i 2018. godine u Kliničkom bolničkom centru Split

  2019cites this paper
• Animal Models of Melanoma

  2019cites this paper
• 50 Jahre Universitäts-Hautklinik am Biederstein in München

  2019cites this paper
• Inhibition of the Myocardin-Related Transcription Factor Pathway Increases Efficacy of Trametinib in NRAS-Mutant Melanoma Cell Lines

  2019cites this paper
• A Comparative Analysis of Individual RAS Mutations in Cancer Biology

  2019influential citation
• Cancer modeling in colorectal organoids reveals intrinsic differences between oncogenic RAS and BRAF variants

  2019cites this paper
• Recent Advances in Melanoma and Melanocyte Biology.

  2017cites this paper
• Différenciation des cellules de la crête neurale lors de l'activation constitutive des protéines NRAS ou BRAF

  2017cites this paper
• Dr. Christian Posch – Preisträger des Österreichischen Wissenschaftspreis der ÖGDV

  2017cites this paper
• Cancer-type dependent expression of CK2 transcripts

  2017cites this paper
• NRAS, NRAS, Which Mutation Is Fairest of Them All?

  2016cites this paper